14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TBPH vs AURA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas AURA carries 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. AURA 28.8/100 SELL) and 0.48β · 2% Vol risk profile, whereas AURA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TBPH vs AURA. Trailing 12-month operating profitability (TBPH 8.9% vs AURA 0.0%) and valuation multiples (TBPH 13.4x vs AURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ TBPH vs AURA Key Questions & Quantitative Answers
As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas AURA carries 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. AURA 28.8/100 SELL) and 0.48β · 2% Vol risk profile, whereas AURA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
TBPH leads the Growth & Scale pillar: TBPH posts -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin), compared with AURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TBPH generates $104M in USD-normalized revenue versus N/A for AURA. In operating R&D and SG&A reinvestment, TBPH deploys 66.2% of Rev ($69M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AURA.
TBPH screens cheaper on headline valuation multiples. TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin), whereas AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TBPH (20.9% ROE) versus AURA (-61.7% ROE) capital efficiency.
In options market volatility and institutional positioning, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk). By comparison, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.